Skip to main content
logo
DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,850.00
+5.00 (0.13%)
At close: Aug 3, 2026

DongKoo Bio & Pharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
50,37650,2722,03611,8126,6149,327
Depreciation & Amortization
8,6938,9197,2746,0285,6325,054
Loss (Gain) From Sale of Assets
-20.09-3.63-5.980-123.891.33
Asset Writedown & Restructuring Costs
4,7214,721665.56--0
Loss (Gain) From Sale of Investments
-57,529-52,191-7,119-2,0778,869-1,090
Loss (Gain) on Equity Investments
-2,979-3,16113,112660.61-118.281,733
Stock-Based Compensation
169.63193.02251.89224.51--
Provision & Write-off of Bad Debts
70.92159.22-193.35-52.8240.44241.76
Other Operating Activities
2,283-2,3792,2951,697331.91638.04
Change in Accounts Receivable
-2,280-251.85478.4-1,333-2,8611,431
Change in Inventory
6,982-5,950-6,632-12,838-6,686-1,897
Change in Accounts Payable
-10,625-10,2874,389-3,0932,7152,399
Change in Other Net Operating Assets
6,0535,672793.422,5582,40465.1
Operating Cash Flow
5,915-4,28717,3443,58516,81917,903
Operating Cash Flow Growth
-47.77%-383.75%-78.68%-6.05%139.06%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-15,684-17,656-21,866-13,845-4,978-4,266
Sale of Property, Plant & Equipment
35.333.6460.66300.4411.97
Sale (Purchase) of Intangibles
-2,404-2,796-3,598-2,034-6,098-1,137
Investment in Securities
-13,093-16,096-18,43311,851-16,2876,202
Other Investing Activities
-656.72-639.7583.28-10639-366.43
Investing Cash Flow
-34,592-38,927-45,033-5,133-27,014463.93

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-63,93747,0297,50015,00070.75
Long-Term Debt Issued
-22,5789,8951,447--
Total Debt Issued
72,25686,51556,9248,94715,00070.75
Short-Term Debt Repaid
--42,436-13,528---
Long-Term Debt Repaid
--1,733-935.5-1,126-5,966-742.12
Total Debt Repaid
-41,303-44,168-14,463-1,126-5,966-742.12
Net Debt Issued (Repaid)
30,95342,34742,4617,8219,034-671.37
Repurchase of Common Stock
---3,408-79.9-2,995-1,998
Dividends Paid
-3,245-3,245-3,313-3,038-2,804-942.94
Other Financing Activities
449.86409.831,45449-50-76.1
Financing Cash Flow
28,15839,51237,1944,7523,185-3,688

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
24.47-109.02154.83-4.74-33.91-2.27
Miscellaneous Cash Flow Adjustments
-0-0--0-0
Net Cash Flow
-494.95-3,8129,6603,199-7,04314,676

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-9,769-21,944-4,522-10,26011,84113,637
Free Cash Flow Growth
-----13.16%514.06%
Free Cash Flow Margin
-4.04%-9.04%-1.81%-4.76%6.07%8.79%
Free Cash Flow Per Share
-342.53-780.52-166.62-371.44426.63482.57
Levered Free Cash Flow
-1,301-35,979-9,684-15,354-140.4310,027
Unlevered Free Cash Flow
967.34-33,786-7,875-14,254509.1410,286

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
3,2803,3032,8281,672902.19362.76
Cash Income Tax Paid
3,0554,3012,7754,1043,0761,392
Change in Working Capital
129.02-10,817-970.91-14,706-4,4271,999